Certara Products - Simcyp Archives | Page 21 of 21

Publication

Using Simcyp to Project Human Oral Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-based Adverse Events

Positive allosteric modulators ('potentiators') of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) have been shown to display…

CertaraMarch 1, 2012

Publication

Physiologically-based Pharmacokinetic Model for Topotecan in Mice

Topotecan is a chemotherapeutic agent of choice for the second-line treatment of recurrent ovarian cancer.…

CertaraFebruary 1, 2011

Publication

Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science

The application of physiologically-based pharmacokinetic (PBPK) modeling is coming of age in drug development and…

CertaraFebruary 1, 2011

Publication

PBPK Modeling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals

Generic PBPK models, applicable to a large number of substances, coupled to parameter databases and…

CertaraDecember 30, 2010

Publication

Physiologically-based Mechanistic Modeling to Predict Complex Drug–drug Interactions Involving Simultaneous Competitive and Time-dependent Enzyme Inhibition by Parent Compound and Its Metabolite in Both Liver and Gut—The Effect of Diltiazem on the Time-course of Exposure to Triazolam

The aim of this study was to predict the magnitude of metabolic drug-drug interaction (mDDI)…

CertaraMarch 18, 2010

Publication

Physiologically-based Pharmacokinetics (PBPK)

Allometric scaling is widely used to predict human pharmacokinetic parameters from preclinical species, and many…

CertaraJune 1, 2009

Publication

Pharmacokinetic Predictions in Children by Using the Physiologically-based Pharmacokinetic Modeling

Nowadays, 50-90% of drugs used in children have never been actually studied in this population. Consequently, either…

CertaraDecember 1, 2008

Publication

The Effects of CYP3A4 Inhibition on Erlotinib Pharmacokinetics: Computer-based Simulation (Simcyp) Predicts In Vivo Metabolic Inhibition

BACKGROUND: Erlotinib is an orally active antitumor agent. Analyses in vitro using human liver microsomes and…

CertaraJanuary 1, 2008

Publication

Physiologically-based Approaches Towards the Prediction of Pharmacokinetics: In Vitro-In Vivo Extrapolation

In adapting to the challenge to make more informed selection of compounds for development, the…

CertaraDecember 1, 2007

Certara Products – Simcyp

Using Simcyp to Project Human Oral Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-based Adverse Events

Physiologically-based Pharmacokinetic Model for Topotecan in Mice

Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science

PBPK Modeling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals

Physiologically-based Mechanistic Modeling to Predict Complex Drug–drug Interactions Involving Simultaneous Competitive and Time-dependent Enzyme Inhibition by Parent Compound and Its Metabolite in Both Liver and Gut—The Effect of Diltiazem on the Time-course of Exposure to Triazolam

Physiologically-based Pharmacokinetics (PBPK)

Pharmacokinetic Predictions in Children by Using the Physiologically-based Pharmacokinetic Modeling

The Effects of CYP3A4 Inhibition on Erlotinib Pharmacokinetics: Computer-based Simulation (Simcyp) Predicts In Vivo Metabolic Inhibition

Physiologically-based Approaches Towards the Prediction of Pharmacokinetics: In Vitro-In Vivo Extrapolation

Newsletter sign up

Quick links

Solutions

Contact